Daratumumab Plus Lenalidomide and Dexamethasone May Benefit Some Patients With MM

Share this content:
Patients were randomly assigned to receive either daratumumab in combination with lenalidomide (an immunomodulatory drug) and dexamethasone (a corticosteroid) or lenalidomide and dexamethasone alone.
Patients were randomly assigned to receive either daratumumab in combination with lenalidomide (an immunomodulatory drug) and dexamethasone (a corticosteroid) or lenalidomide and dexamethasone alone.

Daratumumab, in combination with lenalidomide and dexamethasone, may have more benefits compared with lenalidomide and dexamethasone alone for the treatment of newly diagnosed multiple myeloma (MM) patients who are not candidates for high-dose chemotherapy and autologous stem cell transplant (ASCT), according to interim results from a phase 3 study.1

The study met the primary end point of improving progression-free survival (PFS) at a preplanned interim analysis (hazard ratio [HR], 0.55) resulting in a 45% reduction in the risk of progression or death in patients treated with daratumumab in combination with lenalidomide and dexamethasone. The median PFS for patients treated with the combination therapy had not been reached at the time of analysis, compared with an estimated median PFS of 31.9 months for patients who received lenalidomide and dexamethasone alone.

The researchers reported that no unexpected side effects were seen in this study. Overall, the safety profile of the daratumumab-based combination was consistent with the known safety profiles associated with each drug alone. This is 1 of several studies that has shown that the addition of daratumumab to standard of care in MM may be beneficial.

The phase 3 MAIA study (ClinicalTrials.gov Identifier: NCT02252172) is a randomized, open-label, multicenter study that includes 737 newly diagnosed patients with MM who are not candidates for high-dose chemotherapy and ASCT. Genmab A/S from Copenhagen, Denmark announced the study (MMY3008) results and said it plans to pursue talks with federal regulators to prepare for regulatory filings.

Reference

  1. Genmab announces positive topline results in phase 3 MAIA study of daratumumab in front line multiple myeloma [press release]. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-positive-topline-results-phase-iii-maia-study. Published October 29, 2018. Accessed November 7, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs